Evidence map›Paper›PMID 34586727›Full record

ArticleClinical and translational medicine2021

Dual blocking of PI3K and mTOR signaling by DHW-221, a novel benzimidazole derivative, exerts antitumor activity in human non-small cell lung cancer.

Xiaochun Qin, Mingyue Liu, Yuting Wu, Shu Wang, Siheng Lian, Hui Jia, Qiong Wu, Huaiwei Ding, Qingchun Zhao

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiaochun QinDepartment of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang, China.
Mingyue LiuDepartment of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang, China.
Yuting WuDepartment of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang, China.
Shu WangDepartment of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang, China.
Siheng LianDepartment of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang, China.
Hui JiaDepartment of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China.
Qiong WuDepartment of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China.
Huaiwei DingKey Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.
Qingchun ZhaoDepartment of Life Science and Biochemistry, Shenyang Pharmaceutical University, Shenyang, China.ORCID 0000-0001-9256-9971
Shenyang Pharmaceutical University · CNGeneral Hospital of Shenyang Military Region · CN

Funding

Liaoning Natural Fund Guidance Plan 2019-ZD-0446
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBenzimidazolesTOR Serine-Threonine KinasesAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorHumansLung NeoplasmsMiceMice, NudeMolecular Docking SimulationPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsSignal TransductionXenograft Model Antitumor AssaysAntineoplastic AgentsBenzimidazolesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsTOR Serine-Threonine Kinases

Identifiers

PMID34586727
PMCPMC8473641
OpenAlexW3202158764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.